Business Wire

Panasonic to Team up with IBM Japan in Improving Semiconductor Manufacturing Processes

Share

On October 15, 2019, IBM Japan, Ltd. and Panasonic Corporation’s subsidiary, Panasonic Smart Factory Solutions Co., Ltd. (hereafter "Panasonic"), announced that the companies have agreed to collaborate to develop and market a new high-value-added system to optimize the overall equipment effectiveness (OEE) of customers’ semiconductor manufacturing processes and to realize high-quality manufacturing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191014005718/en/

Aims of the collaboration (Graphic: Business Wire)

Aims of the collaboration (Graphic: Business Wire)

As part of its circuit formation process business, Panasonic currently develops and markets edge devices and manufacturing methods that contribute to improving semiconductor manufacturing of advanced packaging. These new devices and methods include dry etching equipment, plasma dicers to produce high-quality wafers, plasma cleaners that increase metal and resin adhesion and high-accuracy bonding devices. This expertise will be combined with techniques and technology that IBM Japan has developed for semiconductor manufacturing to help Panasonic create smart factory technology. These include a data analysis systems including advanced process control (APC) and fault detection and classification (FDC), as well as an upper-layer manufacturing execution system (MES) — thus improving quality and automating production management in semiconductor manufacturing processes.

In recent years, IoT and 5G devices are becoming faster, smaller, and more multi-functional. This has given rise to manufacturing that is based on advanced packaging technology, in which a middle-end process (that combines the wafer process from the front-end process and the packaging technology from the back-end process) has been added between the front-end and back-end processes in semiconductor manufacturing.

Through the collaboration announced, IBM Japan and Panasonic will jointly develop a data analysis system that will be incorporated into Panasonic’s edge devices. The aim of this high-value-added system is to significantly reduce the number of engineering processes required, to stabilize product quality, and to improve the operating rates of manufacturing facilities. Specifically, the companies intend to develop an automatic recipe generation system for plasma dicers, which is a new advanced packaging production method that is drawing increased attention in the semiconductor manufacturing field, and a process control system that incorporates an FDC system in plasma cleaners — equipment that has demonstrated good results in the back-end process. Going forward, the new system and IBM Japan’s MES will be connected to optimize OEE factory-wide and to realize high-quality manufacturing.

The two companies intend to develop the new system for the back-end process first, then explore an expansion of the scope to the front-end process in the future.

Features of the new high-value-added system

1. Advancing plasma dicers through automatic recipe generation
The computing algorithm jointly developed by the two companies enables customers to enter their desired dicing shape (etching shape), which varies from product to product, and automatically generate equipment parameters consisting of several hundred combinations. This feature is expected to significantly reduce product launch times and engineering costs. It can also be applied to the APC system, which automatically adjusts equipment parameters according to varying processing quality from front- and back-end processes; which will keep processed shapes stable, resulting in a high-quality dicing process.

2. Advancing plasma cleaners through FDC
FDC continuously accumulates operational data from operating manufacturing equipment, detects failures through its own data analysis method, and enables the condition of equipment to be interpreted automatically. This feature generates equipment maintenance target areas and frequency needs, forecasts and prevents failures, optimizes maintenance scheduling, reduces equipment downtime, and improves operating rates.

IBM has been a leader in the IT industry for more than 100 years and a leader in the semiconductor field in R&D of advanced miniaturization processing technology — delivering solid business results at 300mm-semiconductor manufacturing plants across the world. Furthermore, as a solutions provider of production operation systems which enable non-stop full automation at factories, IBM has been contributing to the semiconductor manufacturing field for years. As semiconductors play a vital role in emerging technologies such as IoT and edge-computing, there are growing needs for greater sophistication and miniaturization of semiconductors. Working beyond conventional boundaries, IBM aims to promote the realization of smart factories through co-creation with Panasonic, thus providing new value to society.

Under its "Gemba Process Innovation" vision, Panasonic is expanding its B2B solutions business. The gemba, or physical site for frontline operations, refers to all places where products are made, moved or sold — the places where value is generated and problems must be confronted. By applying the company‘s 100-years of experience and expertise gained in the manufacturing industry with its sensing technologies and edge devices, Panasonic aims to co-create with its customers and partners to solve problems at the gemba. Panasonic is advancing the Gemba Process Innovation vision, aiming to become a total solutions integrator with offerings to the three main areas of manufacturing, logistics, and retail.

About IBM Japan
For more information on IBM Japan, visit https://www.ibm.com/ibm/jp/en/

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2019/10/en191015-2/en191015-2.html

Related Links
Smart Factory Solutions - Business Initiatives
https://www.panasonic.com/global/corporate/management/business-initiatives/factory.html

Factory Automation, Welding Machines - Panasonic Industrial Devices
https://industrial.panasonic.com/ww/products/fa-welding

Panasonic to Exhibit Digital Technology and Products for Smart Factory at CIIF 2019 (Sep 13, 2019)
https://news.panasonic.com/global/topics/2019/71801.html

Panasonic Signs Joint Business Development Agreement with Startup Linkwiz to Enhance Welding Processes in Manufacturing (Jun 17, 2019)
https://news.panasonic.com/global/press/data/2019/06/en190617-3/en190617-3.html

Panasonic Ramps Up Its Smart Factory Solutions Business in India (May 08, 2019)
https://news.panasonic.com/global/topics/2019/67894.html

EV GROUP AND PANASONIC TEAM UP ON RESIST PROCESSING SOLUTION FOR PLASMA DICING (Mar 13, 2019)
https://news.panasonic.com/global/press/data/2019/03/en190313-2/en190313-2.html

Panasonic to Open New B2B 'Customer Experience Center' in Tokyo in January (Dec 17, 2018)
https://news.panasonic.com/global/press/data/2018/12/en181217-2/en181217-2.html

[Video] Expediting Innovations and Co-creation - Panasonic Executive Interview
https://youtu.be/BM9FYnPh-lY

Contact information

IBM Japan
External Relations, TEL: +81-3-3808-5120

Panasonic
Global Communications Department, TEL: +81-3-3574-5664

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom